Solid Tumor Monoclonal B-cell Lymphocytosis Screening

Overview

About this study

The purpose of this study is to determine whether monoclonal B-cell lymphocytosis (MBL) has an impact on clinical outcomes among patients with a diagnosis of a solid tumor.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients in the REP-27 who have been diagnosed with a solid tumor during the last two years and who are 40 years of age or older.

Exclusion Criteria:

Less than 40 years old, no recent solid tumor diagnosis, history of hematologic malignancy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 7/31/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Susan Slager, Ph.D.	Open for enrollment	Contact information: Catherine Erding (507) 284-5522 Erding.Catherine@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Susan Slager, Ph.D.

Open for enrollment

Contact information:

Catherine Erding

(507) 284-5522

Erding.Catherine@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials